Dear friends and colleagues,

We hope you all had a pleasant summer. It is inspiring to see that AMYPAD remains active well beyond the end of the IMI funding period, continuing to make its mark across the world with new publications and conference presentations. Special kudos go to Emma Luckett and Leo Pieperhoff, who both presented AMYPAD findings at the recent AAIC conference in Toronto.

Over the past months, we have made great progress. A new raw dataset is already available on the AD Workbench from the Alzheimer’s Disease Data Initiative, and another data release is in preparation. Looking ahead, we are working hard to secure additional funding through new grant applications. These involve new partners from across Europe, reflecting our transition towards a wider Euro-PAD community. We are also delighted to share that the Euro-PAD protocol has now been approved by the ethics committee, this represents an important milestone for our work.

Before the summer, in June, many of us met in Barcelona for the Euro-PAD scientific symposium. This was a fantastic event for exchange and collaboration and we extend our thanks to BBRC for hosting us, with the kind support of GE HealthCare and Life Molecular Imaging.

Finally, for those attending the upcoming EANM conference in Barcelona, don’t miss the teaching symposium “Nuclear Medicine for Alzheimer’s disease in the Hot Seat: Case Conference on Advancing Early Diagnosis with PET Imaging and Biomarkers” on 6 October (1:15-2:30pm CET), where the AMYPAD Biomarker Qualification opinion for the use of Centiloid quantitative methodology in clinical settings will be featured.

You can download the newsletter here.

Frederik Barkhof
AMYPAD Coordinator